This article is more than 5 years old. Information may no longer be current.

GenSight Biologics closes €32 million in financing for gene therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

GenSight Biologics has raised €32 million in series A financing to help fund development of a gene replacement therapy for Leber’s hereditary optic neuropathy and an optogenetic therapy for retinitis pigmentosa, according to a company news release.

GenSight will make use of its access to intellectual property from Novartis, along with a proprietary approach to targeting mitochondria development in Leber’s hereditary optic neuropathy.

The company expects to bring its lead product for patients with Leber’s hereditary optic neuropathy to clinics this year, the release said.

Novartis Venture Fund, Versant Ventures, Index Ventures and Abingworth LLP co-led the financing, according to the release.